Solventum Corporation (SOLV), with a market capitalization of approximately $14.5 billion, is a global healthcare company that develops solutions using health, material, and data science. The Eagan, Minnesota-based company's technologies help healthcare professionals improve patient outcomes, enhance efficiency, and deliver better, smarter, safer care. Shares of this leading healthcare company have slightly underperformed the broader market over the past year.
SOLV has gained 16.2% over this period, while the broader S&P 500 Index ($SPX) has rallied 20.6%. On a year-to-date basis, SOLV has also underperformed, gaining 9.1% compared with the index's 13.9% gain over the same period. Mark Cuban Says If You Win The Lottery, Don't Take The Lump Sum — And Tell People Who Ask for Money No, But 'Be Nice.
No One Likes a Mean Billionaire' JPMorgan Just Upgraded Salesforce Stock. Why Wall Street Isn't Buying Super Micro's $60 Billion Backlog Quite Yet Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Narrowing the comparison, SOLV has also underperformed the First Trust Health Care AlphaDEX Fund (FXH), which has climbed 25.4% over the past year and gained 15.5% on a YTD basis.
On August 5, Solventum reported its Q2 FY2026 earnings, with shares moving down marginally. Net sales grew 2.2% year over year to $2.21 billion, while organic sales increased 9.5%, reflecting strong performance across all reportable segments. Adjusted EPS rose 50.9% to $2.55 from the prior year's quarter.
Solventum raised its full-year outlook, increasing organic sales growth guidance to 2.50%-3%. The company also lifted its adjusted EPS guidance to $7.10-$7.20, up from the prior $6.40-$6.60 range, while raising its free cash flow outlook to $200 million-$300 million, up from approximately $200 million previously. For the current fiscal year ending in December 2026, analysts expect SOLV's diluted EPS to rise 18.2% to $7.22.
SOLV has surpassed consensus EPS estimates in each of the past four quarters, which is impressive. Among the 16 analysts covering SOLV stock, the consensus rating is a "Moderate Buy." The rating is based on eight "Strong Buys," six "Holds," and two "Strong Sells." SOLV's analyst configuration is more bullish than it was a month ago, when the stock had seven "Strong Buy" recommendations. On August 6, Wells Fargo analyst Nathan Treybeck maintained a "Hold" rating on Solventum Corporation and set an $89 price target.
Extract — continue reading at the source.
